Ashwagandha (Withania somnifera) has become one of the best-selling herbal supplements in the world, marketed as a natural solution for stress, anxiety, and even athletic performance. The term adaptogen—a substance that supposedly helps the body resist stressors—gets attached to it constantly, lending an air of pharmacological legitimacy.

But what does the clinical trial evidence actually look like when you examine it closely? The answer is more nuanced than either enthusiasts or skeptics tend to acknowledge. Some findings are genuinely interesting. Others crumble under methodological scrutiny.

This review evaluates the current state of ashwagandha research across its three most popular claims: cortisol reduction, anxiety relief, and athletic performance enhancement. We'll look at study quality, consistency of findings, and a critical variable that rarely gets enough attention—the enormous variability in what "ashwagandha" actually means from one product to the next.

The most frequently cited evidence for ashwagandha's stress-reducing properties comes from a handful of randomized controlled trials measuring serum cortisol levels. A 2012 study by Chandrasekhar et al. is perhaps the most referenced—it found a significant reduction in serum cortisol (averaging roughly 28%) in subjects taking 600 mg of a root extract daily over 60 days, compared to placebo.

A 2019 systematic review by Lopresti et al., covering five RCTs, concluded that ashwagandha supplementation was associated with reductions in cortisol, perceived stress, and anxiety scores. That sounds compelling. But the total number of participants across those five studies was only around 400, most trials lasted eight weeks or less, and several were conducted by researchers with commercial ties to extract manufacturers.

The cortisol reduction effect, while statistically significant in several trials, tends to be modest in absolute terms. Cortisol is also notoriously variable—it fluctuates with time of day, sleep quality, recent meals, and psychological state at the moment of blood draw. Single-timepoint measurements, which most of these studies relied on, are a weak proxy for overall stress physiology.

Self-reported stress scores (typically using the Perceived Stress Scale) do consistently improve in ashwagandha groups versus placebo. Whether this reflects a genuine pharmacological anxiolytic effect, a robust placebo response amplified by participants' expectations about adaptogens, or some combination remains an open question. The signal is real enough to warrant larger, longer, and more rigorous trials—but it's not yet strong enough to make definitive clinical claims.

Takeaway

A consistent but modest signal across small, short trials is not the same as established clinical evidence. When effect sizes are small and study designs are limited, replication at scale matters more than statistical significance in any single study.

Several trials have examined ashwagandha's effects on strength, cardiorespiratory endurance, and recovery in physically active populations. A commonly cited 2015 study by Wankhede et al. reported that men taking 600 mg of root extract daily during an eight-week resistance training program showed greater increases in muscle strength and size, along with better recovery (measured by muscle damage markers), compared to placebo.

These findings generated considerable excitement in fitness communities. But a closer look reveals important limitations. The study involved only 57 participants, lacked blinding verification, and used a specific proprietary extract (KSM-66). A 2021 systematic review by Bonilla et al. found that while some trials reported improvements in VO₂ max and upper-body strength, results were inconsistent across studies, and most had high or unclear risk of bias.

One recurring problem is the heterogeneity of participant populations. Some studies recruit untrained individuals, where almost any intervention—including consistent training alone—produces measurable improvements. Others use trained athletes, where meaningful performance gains are harder to detect and require larger sample sizes. Pooling these populations in meta-analyses can create misleading summary effects.

The proposed mechanisms—modulation of testosterone, reduction of exercise-induced cortisol, antioxidant activity—are biologically plausible but remain largely speculative at clinically relevant doses in humans. Small elevations in testosterone reported in some trials (typically within normal physiological range) are unlikely to drive meaningful performance changes. Until we see well-powered, pre-registered trials with standardized protocols, athletic performance claims remain premature.

Takeaway

Biological plausibility is not clinical proof. When studies are small and results are inconsistent, the most honest conclusion is 'we don't know yet'—and that's a perfectly valid scientific position.

Perhaps the most underappreciated problem in ashwagandha research is that "ashwagandha" is not a single, uniform substance. Different products use root extract, leaf extract, full-spectrum extract, or combinations. They're standardized to different marker compounds—most commonly withanolides—at concentrations ranging from 1.5% to 35% depending on the preparation.

This matters enormously for interpreting evidence. KSM-66, Sensoril, and Shoden are three commercially available extracts that differ in plant part used, extraction method, and withanolide concentration. A trial showing positive results with Sensoril (derived from roots and leaves, standardized to ≥10% withanolide glycosides) tells you very little about whether a generic root powder at 2.5% withanolides will produce the same effect.

Most systematic reviews and meta-analyses pool results across these different preparations as if they were equivalent. This is a significant methodological weakness. It would be like meta-analyzing studies on "antidepressants" without distinguishing between SSRIs, SNRIs, and tricyclics. The active constituent profile differs substantially, and so may the pharmacological effects.

For consumers, this creates a practical problem: even if the evidence were stronger, knowing which product matches the preparation used in positive trials requires detective work most people aren't equipped to do. Third-party testing has also revealed that some commercial ashwagandha products contain withanolide levels that don't match label claims. Until standardization improves—both in research and in the supplement marketplace—generalized recommendations about ashwagandha remain inherently imprecise.

Takeaway

When a supplement's identity varies dramatically from product to product, positive results from one preparation cannot be automatically extended to another. Standardization isn't a technicality—it's foundational to whether evidence is even transferable to what you're actually taking.

Ashwagandha research contains genuinely interesting signals—particularly for stress and anxiety outcomes—but the evidence base is still early-stage by clinical standards. Small sample sizes, short durations, commercial conflicts of interest, and extract variability all limit the strength of current conclusions.

This doesn't mean ashwagandha is ineffective. It means we don't yet have the quality of evidence needed to make confident clinical recommendations. That distinction matters, especially when supplements are marketed with far more certainty than the science supports.

If you're considering ashwagandha, choose a preparation that matches one used in clinical trials, be realistic about expected effect sizes, and discuss potential interactions with a healthcare provider. Promising is not the same as proven—and being honest about that gap is where good science starts.